Literature DB >> 22463833

Does my patient with a serum monoclonal spike have multiple myeloma?

Giada Bianchi1, Irene M Ghobrial.   

Abstract

A monoclonal spike on serum protein electrophoresis is a frequent finding in the general population and pathognomonic of a plasma cell dyscrasia. In otherwise healthy individuals, it is diagnostic of two asymptomatic, premalignant conditions called monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) which carry a lifelong risk of progression to multiple myeloma (MM) or related malignancy. This article discusses the criteria for diagnosis of MGUS, SMM, and MM; current recommendations for follow-up and risk factors for progression to MM of patients with MGUS and SMM; and diagnostic evaluation of suspected MM transformation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22463833      PMCID： PMC3319353          DOI： 10.1016/j.hoc.2012.02.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  51 in total

Review 1.  Hyperviscosity syndrome in plasma cell dyscrasias.

Authors:  Jayesh Mehta; Seema Singhal
Journal:  Semin Thromb Hemost       Date:  2003-10       Impact factor: 4.180

Review 2.  Cardiac amyloidosis: a practical approach to diagnosis and management.

Authors:  Prashant Kapoor; Thenappan Thenappan; Ekta Singh; Shaji Kumar; Philip R Greipp
Journal:  Am J Med       Date:  2011-11       Impact factor: 4.965

3.  Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts.

Authors:  C Alexiou; R J Kau; H Dietzfelbinger; M Kremer; J C Spiess; B Schratzenstaller; W Arnold
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

4.  A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly.

Authors:  M Bowden; J Crawford; H J Cohen; O Noyama
Journal:  J Am Geriatr Soc       Date:  1993-01       Impact factor: 5.562

5.  Thalidomide for previously untreated indolent or smoldering multiple myeloma.

Authors:  S V Rajkumar; A Dispenzieri; R Fonseca; M Q Lacy; S Geyer; J A Lust; R A Kyle; P R Greipp; M A Gertz; T E Witzig
Journal:  Leukemia       Date:  2001-08       Impact factor: 11.528

6.  Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.

Authors:  Marcus Kremer; German Ott; Michaela Nathrath; Katja Specht; Katrin Stecker; Christoph Alexiou; Leticia Quintanilla-Martinez; Falko Fend
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

7.  [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].

Authors:  Guillermo J Ruiz-Delgado; J David Gómez Rangel
Journal:  Gac Med Mex       Date:  2004 Jul-Aug       Impact factor: 0.302

8.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860
View more
  1 in total

1.  High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.

Authors:  G Bianchi; R A Kyle; D R Larson; T E Witzig; S Kumar; A Dispenzieri; W G Morice; S V Rajkumar
Journal:  Leukemia       Date:  2012-08-20       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.